The Tyrosine Protein Kinase SYK pipeline drugs market research report outlays comprehensive information on the Tyrosine Protein Kinase SYK targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Tyrosine Protein Kinase SYK pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

The report also covers products from therapy areas such as Immunology, Oncology, Ophthalmology, and Hematological Disorders which include the indications Rheumatoid Arthritis, Systemic Lupus Erythematosus, Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Allergic Conjunctivitis, Keratoconjunctivitis Sicca (Dry Eye), Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), and Acquired (Autoimmune) Hemolytic Anemia. It also reviews key players involved in Tyrosine Protein Kinase SYK targeted therapeutics development with respective active and dormant or discontinued products.

The Tyrosine Protein Kinase SYK pipeline targets constitutes close to 28 molecules. Out of which, approximately 28 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 1, 1, 11, 2, 11, and 2 respectively.

Tyrosine Protein Kinase SYK overview

Spleen tyrosine kinase, also known as Syk, is an enzyme encoded by the SYK gene. It regulates several biological processes including innate and adaptive immunity, cell adhesion, osteoclast maturation, platelet activation and vascular development. It assembles into signaling complexes with activated receptors at the plasma membrane via interaction between its SH2 domains and the receptor tyrosine-phosphorylated ITAM domains. The association with the receptor can also be indirect and mediated by adapter proteins containing ITAM or partial hemITAM domains. The phosphorylation of the ITAM domains is generally mediated by SRC subfamily kinases upon engagement of the receptor. More rarely signal transduction via SYK could be ITAM-independent.

For a complete picture of Tyrosine Protein Kinase SYK’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.